Clinical Trial Update: Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients

View source ↗

Summary

An observational prospective study investigating cardiovascular and renal outcomes of SGLT2 inhibitors (flozins) in CKD patients with heart failure with preserv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Diabetes Mellitus
• Heart Failure with Preserved Ejection Fraction

Drugs mentioned

• SGLT2 inhibitors (flozins)

Snippet

Sponsor: Grigore T. Popa University of Medicine and Pharmacy | Conditions: CKD - Chronic Kidney Disease, Heart Failure Preserved Ejection Fraction | Status: RECRUITING